[go: up one dir, main page]

WO1993000427A3 - Facteurs regulateurs de la croissance des neurites - Google Patents

Facteurs regulateurs de la croissance des neurites Download PDF

Info

Publication number
WO1993000427A3
WO1993000427A3 PCT/EP1992/001384 EP9201384W WO9300427A3 WO 1993000427 A3 WO1993000427 A3 WO 1993000427A3 EP 9201384 W EP9201384 W EP 9201384W WO 9300427 A3 WO9300427 A3 WO 9300427A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
metalloproteases
treatment
myelin associated
malignant tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1992/001384
Other languages
English (en)
Other versions
WO1993000427A2 (fr
Inventor
Martin E Schwab
Pierenrico W Caroni
Paolo A Paganetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANTON ZURICH ERZIEHUNGSDIREKTION
CANTON ZURICH ERZIEHUNGSDIREKT
Original Assignee
CANTON ZURICH ERZIEHUNGSDIREKTION
CANTON ZURICH ERZIEHUNGSDIREKT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/719,692 external-priority patent/US5250414A/en
Application filed by CANTON ZURICH ERZIEHUNGSDIREKTION, CANTON ZURICH ERZIEHUNGSDIREKT filed Critical CANTON ZURICH ERZIEHUNGSDIREKTION
Publication of WO1993000427A2 publication Critical patent/WO1993000427A2/fr
Publication of WO1993000427A3 publication Critical patent/WO1993000427A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Gènes et protéines codées de ceux-ci servant à réguler la croissance des neurites, et utilisations diagnostique et thérapeutique de ces protéines (ci-après: facteurs régulateurs de la croissance des neurites). Lesdites protéines incluent des protéines associées à la myéline du système nerveux central (CNS) et des métalloprotéases associées aux cellules de glioblastomes et aux autres tumeurs malignes aptes à métastaser dans le cerveau. Les protéines associées à la myéline du CNS inhibent l'excroissance de neurites dans les cellules nerveuses et les cellules de neuroblastomes, et peuvent également inhiber la propagation fibroblastique. Ces protéines d'inhibition incluent des protéines dont les poids moléculaires sont de 35 000 et 250 000 daltons respectivement, leurs analogues, leurs dérivés et leurs fragments. Lesdites protéines d'inhibition associées à la myéline du CNS peuvent être utilisées dans le traitement des tumeurs malignes. Lesdites métalloprotéases sont utiles dans le traitement des lésions nerveuses et des troubles dégénératifs du système nerveux. On a également prévu des inhibiteurs des métalloprotéases pouvant s'utiliser, en association avec lesdites protéines d'inhibition associées à la myéline du CNS, dans le traitement des tumeurs malignes.
PCT/EP1992/001384 1991-06-24 1992-06-19 Facteurs regulateurs de la croissance des neurites Ceased WO1993000427A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US719,692 1991-06-24
US07/719,692 US5250414A (en) 1988-11-04 1991-06-24 Diagnostic methods using neurite growth regulatory factors

Publications (2)

Publication Number Publication Date
WO1993000427A2 WO1993000427A2 (fr) 1993-01-07
WO1993000427A3 true WO1993000427A3 (fr) 1993-04-29

Family

ID=24891002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1992/001384 Ceased WO1993000427A2 (fr) 1991-06-24 1992-06-19 Facteurs regulateurs de la croissance des neurites

Country Status (2)

Country Link
AU (1) AU2152092A (fr)
WO (1) WO1993000427A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2117889A1 (fr) * 1993-02-11 1994-08-18 Martin E. Schwab Methode favorisant la regeneration du systeme nerveux central qui combine une neurotrophine et un anticorps dirige contre une proteine inhibant la croissance des neurites et associee a la myeline
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
CA2218599A1 (fr) * 1995-04-19 1996-10-24 Acorda Therapeutics Modulateurs de la croissance de l'axone et des dendrites du systeme nerveux central, compositions, cellules et procedes dans lesquels ils sont mis en oeuvre et utilises
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
ATE435232T1 (de) 1998-11-06 2009-07-15 Univ Zuerich Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000060064A1 (fr) * 1999-04-01 2000-10-12 The Procter & Gamble Company Processus de purification d'une enzyme du type fixant le calcium, par exemple une métalloprotéase, à l'aide d'un tampon exempt de calcium
US7186530B1 (en) 2000-04-07 2007-03-06 Chiron Corporation Protein associated with cell stress response
WO2000060083A1 (fr) * 1999-04-08 2000-10-12 Chiron Corporation Nouvelle proteine associee a la reponse de la cellule a un stress

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0046523A1 (fr) * 1980-08-26 1982-03-03 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Détergents zwittérioniques non-dénaturants pour la biochimie de membranes
WO1990005191A1 (fr) * 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Facteurs de regulation de la croissance des neurites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0046523A1 (fr) * 1980-08-26 1982-03-03 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Détergents zwittérioniques non-dénaturants pour la biochimie de membranes
WO1990005191A1 (fr) * 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Facteurs de regulation de la croissance des neurites

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Experientia, vol. 46, March 1990, (Basel, CH) P.A. Paganetti et al.: "Glioblastoma infiltration into CNS tissue in vitro: the role of a metalloprotease", see abstract, & 22nd Annual Meeting of the Swiss Societies for Experimental Biology, March 15/16, 1990, Z}rich *
EXPERIMENTAL NEUROLOGY vol. 115, no. 1, January 1992, NEW YORK, US pages 189 - 192 D.S. CADELLI ET AL. 'Oligodendrocyte- and Myelin-Associated Inhibitors of Neurite Outgrowth: Their Involvement in the Lack of CNS Regeneration' *
J. CELL BIOL. vol. 107, no. 6, December 1988, NEW YORK, US pages 2281 - 2291 P. A. PAGANETTI ET AL. 'Glioblastoma Infiltration into Central Nervous System Tissue in Vitro: Involvement of a Metalloprotease' cited in the application *
J. Cell Biol., vol. 107, no. 6, December 1988 (New York, US) P.A. Paganetti et al.: "Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloprotease", pages 2281-2291, see abstract; page 2282, right-hand column, paragraphs 1-2 (cited in the application) *
J. CELL. BIOL. vol. 106, no. 4, April 1988, NEW YORK, US P. CARONI & M.E. SCHWAB 'Two Membrane Protein Fractions from Rat Central Myelin with Inhibitory Properties for Neurite Growth and Fibroblast Spreading' cited in the application *

Also Published As

Publication number Publication date
AU2152092A (en) 1993-01-25
WO1993000427A2 (fr) 1993-01-07

Similar Documents

Publication Publication Date Title
AU7435494A (en) Neurite growth regulatory factors
MX9604985A (es) Cardiotropina y usos de la misma.
NO991951L (no) Tienopyrimidiner med fosfodiesterase V-inhiberende virkning
WO1993000427A3 (fr) Facteurs regulateurs de la croissance des neurites
RU94046424A (ru) Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
CA2120303A1 (fr) Inhibiteurs cycliques de l'adhesion
HU9600832D0 (en) Inhibitors of beta-amyloid protein production
BG105643A (en) Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds
EP1158985A4 (fr) DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
IL192287A0 (en) Pharmaceutical compositions and methods for use
DE69616792D1 (de) Verwendung von lemellarin alkaloiden in therapeutischen verfahren
GR3003452T3 (en) Indolocarbazole derivatives, processes for their preparation and their use as medicaments
EP0319315A3 (fr) Domaine du facteur VIII liant le facteur de von Willebrand
WO2000071520A3 (fr) Compositions pharmaceutiques et methodes d'utilisation
WO2002005801A3 (fr) Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
EP0383171A3 (fr) Dérivés de 2,3,23 trihydroxy-urs-12-ène pour le traitement des troubles cognitifs
WO1999029640A3 (fr) Compositions et procedes permettant de moduler l'activite du facteur de croissance des fibroblastes
WO1997014966B1 (fr) Procede d'activation d'une nouvelle voie de regulation de ligand
WO2001082954A3 (fr) Ceruloplasmine et ses utilisations dans le cadre de troubles lies a la neurodegenerescence
WO1994024279A3 (fr) Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA